Related Experiment Video
Updated: Nov 9, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India
Lakshmi Lavanya Reddy1, Swarup A V Shah2, Chandrashekhar K Ponde3
1Research Laboratories, P. D Hinduja Hospital & Medical Research Centre, Mumbai, India.
Insights
This study investigated Familial Hypercholesterolemia (FH) in India, finding no pathogenic variants in the PCSK9 gene but identifying known pathogenic variants in the LDLR gene. Elevated PCSK9 levels correlated with high cholesterol in FH patients.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Biochemistry
Background:
- Familial Hypercholesterolemia (FH) is a prevalent genetic disorder causing high LDL-cholesterol and increased Coronary Artery Disease (CAD) risk.
- Limited genetic studies on non-LDLR genes exist in the Indian population, necessitating further investigation.
Purpose of the Study:
- To screen the entire PCSK9 gene and hotspot exons of the LDLR gene in Indian FH cases and controls.
- To assess the clinical relevance of PCSK9 variants and circulating PCSK9 levels in FH.
Main Methods:
- Screening of all 12 PCSK9 exons and hotspot LDLR exons (3, 4, 9) using High Resolution Melt (HRM) analysis.
- Measurement of serum PCSK9 levels via Enzyme Linked Immunosorbent Assay (ELISA).
- Categorization of 50 FH cases based on Dutch Lipid Network Criteria (DLNC), matched with 50 controls.
Main Results:
- No pathogenic variants were identified in the PCSK9 gene; 8 non-pathogenic variants were detected.
- Three known pathogenic variants and one benign variant were found in the LDLR gene (exons 3 & 4).
- Circulating PCSK9 levels were significantly elevated in FH cases and directly correlated with Total Cholesterol and LDL-C.
Conclusions:
- PCSK9 variants may have limited clinical relevance in the studied Indian FH cohort.
- Pathogenic variants in the LDLR gene contribute to FH in India.
- This study provides crucial insights into the genetic landscape of FH in Western India.
Abstract:
Familial Hypercholesterolemia (FH) is an autosomal, dominant, inherited disorder characterized by severely elevated LDL-cholesterol (LDL-C) levels with high risk for Coronary Artery Disease (CAD). There are limited genetic studies especially on genes other than Low Density Lipoprotein receptor (LDLR) conducted in Indian population. Thus, our aim was to screen the entire Proprotein Convertase Subtilisin/Kexin type 9 gene (PCSK9) gene & hotspot exons 3, 4 and 9 of LDLR gene in FH cases and controls. 50 FH cases were categorized into definite, probable and possible cases according to Dutch Lipid Network Criteria (DLNC) who were gender matched with 50 healthy controls. All 12 exons of PCSK9, and hotspot exons 3, 4 & 9 of LDLR gene were screened through High Resolution Melt (HRM) curve analysis. Enzyme linked immunosorbent assay was performed to measure circulating PCSK9 levels. Total cholesterol and LDL-C were significantly high in all three groups of cases. Total 8 nonpathogenic variants in exon 1, 5, 7 and 9 of the PCSK9 gene were detected. In LDLR gene, 3 known pathogenic and 1 benign variant were found in exon 3 & 4. In FH cases, PCSK9 levels were significantly high compared to controls (P = 0.0001), and were directly correlated to LDL-C (P = 0.0001) and Total Cholesterol (P = 0.0001). Our study is first to screen the entire PCSK9 gene in western part of India. Since no pathogenic variants were identified, it is possible that PCSK9 variants are clinically less relevant. However, 3 known pathogenic variants were found in the LDLR gene. These findings support our understanding of the genetic spectrum of FH in India.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...

